Tempus Q1 revenue up 75.4% to $255.7M; raises FY2025 revenue guidance to $1.25B

Tempus AI, Inc.

2025-Q1 EPS reported -$0.40 revenue$255,737,000

Revenue $255.7M (+75.4% YoY); gross profit $155.2M (+99.8% YoY) with margin improvement in Genomics and Data & Services.
Net loss $68.0M (incl. $28.2M stock comp & $31.8M fair value losses); adjusted EBITDA -$16.2M vs -$43.9M YoY.
Collaborations with AstraZeneca and Pathos; $200M in data licensing/model development fees over 3 years.
Full year 2025 revenue guidance raised to ~$1.25B (~80% growth); expects positive adjusted EBITDA of $5M.
Genomics revenue $193.8M (+88.9% YoY); Data & Services revenue $61.9M (+43.2% YoY; Insights up 58%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.